Search

Calcific aortic valve disease (CAVD) is a common acquired valvular heart disease that may cause heart failure and sudden cardiac death. However, there is currently no effective interventions to prevent or slow down the CAVD. Recent studies have found that lipoprotein a [Lp(a)] is closely related to the occurrence and development of CAVD. This article reviews the mechanism, clinical research, and potential therapeutic targets of Lp(a) and CAVD, in order to improve the understanding of the clinical prevention and treatment of Lp(a) and CAVD. [ABSTRACT FROM AUTHOR]